# To Evaluate the Effect of MCS® in Prostate Cancer Prevention

> **NCT02042807** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Health Ever Bio-Tech Co., Ltd.** · enrollment: 702 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Placebo
- **DRUG:** MCS®

## Key facts

- **NCT ID:** NCT02042807
- **Lead sponsor:** Health Ever Bio-Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-10
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 702 (ESTIMATED)
- **Last updated:** 2024-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02042807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02042807, "To Evaluate the Effect of MCS® in Prostate Cancer Prevention". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02042807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*